OBJECTIVE: The ENGAGE registry was undertaken to examine the real-world outcome after endovascular abdominal aortic aneurysm (AAA) repair (EVAR) with the Endurant Stent Graft in a large, contemporary, global series of patients. METHODS:From March 2009 to April 2011, 1262 AAA patients (89.6% men; mean age 73.1 years, range 43-93 years) were enrolled from 79 sites in 30 countries and treated with Endurant. Results are described following the reporting standards for EVAR. Follow-up data were tabulated for all 1262 patients at a 30-day follow-up and for the first 500 patients at a 1-year follow-up. RESULTS:Intra-operative technical success was achieved in 99.0% of cases. Within 30 days, adverse events were reported in 3.9% of patients, including a 1.3% mortality rate. Type-I or -III endoleaks were identified in 1.5% of cases. Estimated overall survival, aneurysm-related survival and freedom from secondary interventions at 1 year were 91.6%, 98.6% and 95.1%, respectively. At 1 year, aneurysm size increased ≥ 5 mm in 2.8% and decreased ≥ 5 mm in 41.3% of cases. CONCLUSION: Early results from this real world, global experience are promising and indicate that endovascular AAA repair with the Endurant Stent Graft is safe and effective across different geographies and standards of practice. Longer-term follow-up is necessary to assess durability of these results.
RCT Entities:
OBJECTIVE: The ENGAGE registry was undertaken to examine the real-world outcome after endovascular abdominal aortic aneurysm (AAA) repair (EVAR) with the Endurant Stent Graft in a large, contemporary, global series of patients. METHODS: From March 2009 to April 2011, 1262 AAA patients (89.6% men; mean age 73.1 years, range 43-93 years) were enrolled from 79 sites in 30 countries and treated with Endurant. Results are described following the reporting standards for EVAR. Follow-up data were tabulated for all 1262 patients at a 30-day follow-up and for the first 500 patients at a 1-year follow-up. RESULTS: Intra-operative technical success was achieved in 99.0% of cases. Within 30 days, adverse events were reported in 3.9% of patients, including a 1.3% mortality rate. Type-I or -III endoleaks were identified in 1.5% of cases. Estimated overall survival, aneurysm-related survival and freedom from secondary interventions at 1 year were 91.6%, 98.6% and 95.1%, respectively. At 1 year, aneurysm size increased ≥ 5 mm in 2.8% and decreased ≥ 5 mm in 41.3% of cases. CONCLUSION: Early results from this real world, global experience are promising and indicate that endovascular AAA repair with the Endurant Stent Graft is safe and effective across different geographies and standards of practice. Longer-term follow-up is necessary to assess durability of these results.
Authors: Thomas F X O'Donnell; Hence J Verhagen; Giovanni Pratesi; Carlo Pratesi; Joep A W Teijink; Frank E G Vermassen; Patrice Mwipatayi; Thomas L Forbes; Marc L Schermerhorn Journal: J Vasc Surg Date: 2019-08-30 Impact factor: 4.268
Authors: Sarah E Deery; Katie E Shean; Alexander B Pothof; Thomas F X O'Donnell; Barbara A Dalebout; Jeremy D Darling; Thomas C F Bodewes; Marc L Schermerhorn Journal: Ann Vasc Surg Date: 2018-03-02 Impact factor: 1.466
Authors: Ignacio M Bluro; Fernando Garagoli; Norberto B Fiorini; José M Rabellino; José G Chas; Alberto Domenech; Vadim Kotowicz; Rodolfo Pizarro Journal: Arch Cardiol Mex Date: 2022-04-04
Authors: Raman Uberoi; Carlo Setacci; Mario Lescan; Antonio Lorido; David Murray; Zoltán Szeberin; Tomasz Zubilewicz; Vincent Riambau; Angsu Chartrungsan; Jörg Tessarek Journal: J Endovasc Ther Date: 2018-10-03 Impact factor: 3.487